Sailong Pharmaceutical Group Co (SZSE:002898) Total Liabilities : ¥246.8 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Sailong Pharmaceutical Group Co Total Liabilities?

Sailong Pharmaceutical Group Co's Total Liabilities for the quarter that ended in Mar. 2024 was ¥246.8 Mil.

Sailong Pharmaceutical Group Co's quarterly Total Liabilities declined from Sep. 2023 (¥281.96 Mil) to Dec. 2023 (¥277.96 Mil) and declined from Dec. 2023 (¥277.96 Mil) to Mar. 2024 (¥246.80 Mil).

Sailong Pharmaceutical Group Co's annual Total Liabilities increased from Dec. 2021 (¥319.12 Mil) to Dec. 2022 (¥321.67 Mil) but then declined from Dec. 2022 (¥321.67 Mil) to Dec. 2023 (¥277.96 Mil).

Sailong Pharmaceutical Group Co Total Liabilities Historical Data

The historical data trend for Sailong Pharmaceutical Group Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sailong Pharmaceutical Group Co Total Liabilities Chart

Sailong Pharmaceutical Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

176.95

229.69

319.12

321.67

277.96

Sailong Pharmaceutical Group Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															297.71	327.88	281.96	277.96	246.80

Sailong Pharmaceutical Group Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sailong Pharmaceutical Group Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	227.01	+	(25.118	+	25.834
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	278.0

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	813.844	-	535.882
	=	278.0

Sailong Pharmaceutical Group Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	200.221	+	(22.878	+	23.703
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	246.8

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	784.308	-	537.506
	=	246.8

Sailong Pharmaceutical Group Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Sailong Pharmaceutical Group Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sailong Pharmaceutical Group Co (SZSE:002898) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sailong Pharmaceutical Group Co Ltd (SZSE:002898) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 47, Haibin South Road, 2nd Floor, Everbright International Trade Center, Guangdong Province, Zhuhai, CHN, 519015

Website

http://www.sailong.cn

Zhuhai Sailong Pharmaceutical Co Ltd is the pharmaceutical company. It is mainly engaged in the development, production, marketing and technical services of pharmaceuticals. The company's products are mainly concentrated in the fields of the nervous system, cardiovascular and digestive system. The product range includes monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others.

Executives

Tang Lin	Director
Long Zhi Xiang	Director
Deng Yong Jun	Supervisors
Zhou Bei	Supervisors
Li Jian Feng	Directors, executives

Sailong Pharmaceutical Group Co (SZSE:002898) Headlines

No Headlines